# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Liquidia Corporation (NASDAQ:LQDA) (Liquidia), a biopharmaceutical company developing innovative therapies for patients with ra...
Liquidia Corporation (NASDAQ:LQDA) (the "Company" or "Liquidia"), a biopharmaceutical company developing innova...
HC Wainwright & Co. analyst Andrew Fein reiterates Liquidia (NASDAQ:LQDA) with a Buy and maintains $29 price target.
Needham analyst Serge Belanger reiterates Liquidia (NASDAQ:LQDA) with a Buy and maintains $19 price target.
FDA granted tentative approval of YUTREPIA (treprostinil) inhalation powder to treat pulmonary arterial hypertension (PAH) and ...
PayPal CEO Alex Chriss "is a very good manager," Cramer said. Plus: AST SpaceMobile, Flutter Entertainment and more.